A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors

被引：0
|
作者：
Papadopoulos, K. [1 ]
Tolcher, A. [1 ]
Kittaneh, M. [2 ]
Patniak, A. [1 ]
Rasco, D. [1 ]
Chambers, G. [1 ]
Newth, G. [2 ]
Savage, R. [3 ]
Hall, T. [3 ]
Schwartz, B. [3 ]
Kazakin, J. [3 ]
LoRusso, P. [2 ]
机构：
[1] South Texas Accelerated Res Therapeut, Med Oncol, San Antonio, TX USA
[2] Karmanos Canc Inst, Ctr Translat Therapeut, Detroit, MI USA
[3] ArQule Inc, Clin Dev, Woburn, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70515-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [31] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
    Rosen, Lee S.
    Senzer, Neil
    Mekhail, Tarek
    Ganapathi, Ram
    Chai, Feng
    Savage, Ronald E.
    Waghorne, Carol
    Abbadessa, Giovanni
    Schwartz, Brian
    Dreicer, Robert
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7754 - 7764
  • [33] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
    Nemunaitis, John J.
    Small, Karen A.
    Kirschmeier, Paul
    Zhang, Da
    Zhu, Yali
    Jou, Ying-Ming
    Statkevich, Paul
    Yao, Siu-Long
    Bannerji, Rajat
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [35] A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
    John J Nemunaitis
    Karen A Small
    Paul Kirschmeier
    Da Zhang
    Yali Zhu
    Ying-Ming Jou
    Paul Statkevich
    Siu-Long Yao
    Rajat Bannerji
    Journal of Translational Medicine, 11
  • [36] TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial
    Naing, Aung
    Mckean, Meredith
    Tolcher, Anthony
    Victor, Anja
    Hu, Ping
    Gao, Wei
    Filho, Marco A. F. Nogueira
    Kitzing, Thomas
    Gleicher, Stephan
    Holland, Daniel
    Richter, Emilia
    Tadjalli-Mehr, Keyvan
    Siu, Lillian L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [37] A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
    Ribrag, Vincent
    Iglesias, Lara
    De Braud, Filippo
    Ma, Brigette
    Yokota, Tomoya
    Zander, Thomas
    Spreafico, Anna
    Subbiah, Vivek
    Illert, Anna L.
    Tan, Daniel
    Santoro, Armando
    Munster, Pamela N.
    Suehiro, Youko
    Wang, Yongsheng
    Ji, Dong-Mei
    Chen, Shuqi
    Beltz, Karen
    Suenaga, Naoko
    Ramkumar, Thiruvamoor
    Luo, Fangjun
    Lai, Clinton
    Wainberg, Zev A.
    EUROPEAN JOURNAL OF CANCER, 2025, 216
  • [38] Determination of FGF-19, 21, and 23 protein levels in a phase I clinical trial of ARQ 087, an oral pan-FGFR inhibitor
    Hall, Terence
    Kazakin, Julia
    Schwartz, Brian
    Savage, Ronald
    CANCER RESEARCH, 2015, 75
  • [39] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
    Yap, T. A.
    Choudhury, A. D.
    Hamilton, E.
    Rosen, L. S.
    Stratton, K. L.
    Gordon, M. S.
    Schaer, D.
    Liu, L.
    Zhang, L.
    Mittapalli, R. K.
    Zhong, W.
    Soman, N.
    Tolcher, A. W.
    ESMO OPEN, 2024, 9 (09)
12345